Premium
Impact of pneumococcal polysaccharide vaccine in people aged 65 years or older
Author(s) -
Menzies Robert I,
Krause Vicki L,
McIntyre Peter B
Publication year - 2014
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/mja14.00399
Subject(s) - pneumococcal polysaccharide vaccine , pneumococcal vaccine , medicine , pneumococcal disease , biology , streptococcus pneumoniae , microbiology and biotechnology , antibiotics
Results: The proportion of people aged 65 years who were vaccinated within the previous 5 years in jurisdictions excluding Victoria ranged from 41% to 64% over the study period, with no clear trend over time. Incidence rate ratios in the 65-year age group were 0.11 (95% CI, 0.09–0.14) for 7vPCV serotypes, 1.64 (95% CI, 1.41–1.91) for 23vPPV–non-7vPCV serotypes and 2.07 (95% CI, 1.67– 2.57) for non-23vPPV serotypes. The incidence rate ratio for total IPD was 0.65 (95% CI, 0.59–0.71) for people aged 65 years, and 0.80 (0.71–0.90) for people aged 50–64 years. The estimate of 23vPPV effectiveness was 61.1% (95% CI, 55.1%–66.9%).